Polycyclic compounds as soluble epoxide hydrolase inhibitors

In this invention, a novel family of benzohomoadamantane-based soluble epoxide hydrolase inhibitors is disclosed. The benzohomoadamantane scaffold is a polycyclic, readily accessible, system that features a homoadamantane unit fused with an aromatic ring. Although it has been scarcely used in medicinal chemistry, it is very versatile and permits several chemical derivatizations in its structure in order to improve the inhibitory activity and/or the DMPK properties of the compounds. This invention encompasses ureas, amides, carbamates and thioureas. The compounds are of interest for the broad range of therapeutic indications related to the inhibition of soluble epoxide hydrolase, including inflammatory diseases, pain and neurodegeneration. This invention has been licensed to a US-based start-up that is actively recruiting investors and strategic partners for advancing a selected candidate to regulatory studies.

Authors

Institutions

Publication Details

Journal
Invention Disclosure
Published
2025-03-15
DOI
https://doi.org/10.1016/j.inv.2025.100039
Primary Topic
Eicosanoids and Hypertension Pharmacology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Polycyclic compounds as soluble epoxide hydrolase inhibitors

Sandra Codony, Santiago Vázquez, René Leiva, Andreea L. Turcu et al.
Invention Disclosure
Eicosanoids and Hypertension Pharmacology
article

Polycyclic compounds as soluble epoxide hydrolase inhibitors

Sandra Codony, Santiago Vázquez, René Leiva, Andreea L. Turcu, Carles Galdeano, Elena Valverde
article en

Abstract

In this invention, a novel family of benzohomoadamantane-based soluble epoxide hydrolase inhibitors is disclosed. The benzohomoadamantane scaffold is a polycyclic, readily accessible, system that features a homoadamantane unit fused with an aromatic ring. Although it has been scarcely used in medicinal chemistry, it is very versatile and permits several chemical derivatizations in its structure in order to improve the inhibitory activity and/or the DMPK properties of the compounds. This invention encompasses ureas, amides, carbamates and thioureas. The compounds are of interest for the broad range of therapeutic indications related to the inhibition of soluble epoxide hydrolase, including inflammatory diseases, pain and neurodegeneration. This invention has been licensed to a US-based start-up that is actively recruiting investors and strategic partners for advancing a selected candidate to regulatory studies.

Invention DisclosureVol. 5
Universitat de Barcelona (ES)
Generalitat de Catalunya, Universitat de Barcelona, Fundació Bosch i Gimpera, Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España, European Regional Development Fund
Openalex Percentile: Top 95%
Eicosanoids and Hypertension Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.